MLN3897

DB06505ExperimentalSmall molecule

MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

Mechanism: MLN3897 is a novel specific antagonist of the chemokine receptor CCR1. It inhibits osteoclastogenesis and osteoclast (OC) activity by impairing multinucleation and by down-regulation of c-fos signaling. CCR1 inhibition by MLN3897 blocks ERK pathway activation and c-fos expression and results in impaired monocyte multinucleation process as well as cathepsin K expression.
Curator reviewed
Primary indication: Investigated for use/treatment in inflammatory disorders (unspecified) and rheumatoid arthritis.Curator reviewed
Formula / weight: C₃₂H₃₇ClN₂O₃ · 533.11 g/mol (avg)
Also known as: (4S)-4-(4-CHLOROPHENYL)-1-((3E)-3-(9-(1-HYDROXY-1-METHYL-ETHYL)-5H-(1)BENZOXEPINO(3,4-B)PYRIDIN-11-YLIDENE)PROPYL)-3,3-DIMETHYL-PIPERIDIN-4-OL · BENZOXEPINO(3,4-B)PYRIDINE-7-METHANOL, 5-(3-((4S)-4-(4-CHLOROPHENYL)-4-HYDROXY-3,3-DIMETHYL-1-PIPERIDINYL)PROPYLIDENE)-5,11-DIHYDRO-.ALPHA.,.ALPHA.-DIMETHYL-
Code names: AVE-9897

Resolves to

Compound

Structure

InChIKeyZGFJFBOLVLFLLN-MOLVWPNASA-NSMILESCC(C)(O)C1=CC=C2OCC3=C(C=CC=N3)\C(=C/CCN3CC[C@](O)(C4=CC=C(Cl)C=C4)C(C)(C)C3)C2=C1

Targets

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with MLN3897, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.